**Question:** Cryoprecipitate contains all except

A. Antithrombin III
B. Fibrinogen
C. Platelets
D. Von Willebrand factor

**Core Concept:** Cryoprecipitate is a plasma product prepared from frozen plasma, which is obtained from pooled human blood. It is used to treat bleeding disorders due to low levels of clotting factors in plasma.

**Why the Correct Answer is Right:** Cryoprecipitate contains several clotting factors, including factor VIII, IX, X, and XI, which are essential for blood clotting. These factors are precipitated during the freezing process, separating them from other components of plasma.

Cryoprecipitate does not contain platelets, a component of the blood that participates in primary hemostasis and plays a role in secondary hemostasis by facilitating platelet aggregation and clot retraction. Platelets are not precipitated during the freezing process of cryoprecipitate preparation.

**Why Each Wrong Option is Incorrect:**

A. Antithrombin III: This is a plasma protein that inhibits various clotting factors, particularly factor Xa and thrombin. Antithrombin III is not removed during the freezing process of cryoprecipitate preparation, making option A incorrect.

B. Fibrinogen: Fibrinogen is a plasma protein that is converted to fibrin monomers during clot formation, leading to fibrin polymerization and clot formation. Fibrinogen is not precipitated during the freezing process of cryoprecipitate preparation, making option B incorrect.

C. Platelets: As explained earlier, cryoprecipitate does not contain platelets due to the absence of platelet removal during the freezing process. This makes option C incorrect.

D. Von Willebrand factor: Von Willebrand factor (VWF) is a plasma protein that binds to platelet glycoprotein receptors, promoting platelet adhesion and aggregation at sites of vascular injury. VWF is not specifically removed during the freezing process of cryoprecipitate preparation, making option D incorrect.

**Clinical Pearl:** The presence of platelets and Von Willebrand factor in cryoprecipitate makes it unsuitable for treating bleeding disorders caused by platelet dysfunction or von Willebrand disease. Instead, these conditions require concentrates specific to platelets (platelet concentrates) and Von Willebrand factor (von Willebrand factor concentrate), respectively.